Protein degraders enter the clinic—a new approach to cancer therapy
D Chirnomas, KR Hornberger, CM Crews - Nature Reviews Clinical …, 2023 - nature.com
Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC)
protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural …
protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural …
The 2022 World Health Organization classification of tumors of the urinary system and male genital organs—part B: prostate and urinary tract tumors
Abstract The 2022 World Health Organization (WHO) classification of the urinary and male
genital tumors was recently published by the International Agency for Research on Cancer …
genital tumors was recently published by the International Agency for Research on Cancer …
Androgen receptor activity in T cells limits checkpoint blockade efficacy
Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-
tumour immunity in solid tumours. In patients with advanced prostate cancer …
tumour immunity in solid tumours. In patients with advanced prostate cancer …
Mutational signatures: emerging concepts, caveats and clinical applications
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
The genecards suite
The GeneCards® database of human genes was launched in 1997 and has expanded
since then to encompass gene-centric, disease-centric, and pathway-centric entities and …
since then to encompass gene-centric, disease-centric, and pathway-centric entities and …
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives
X Shi, X Wang, W Yao, D Shi, X Shao, Z Lu… - Signal transduction and …, 2024 - nature.com
Metastasis remains a pivotal characteristic of cancer and is the primary contributor to cancer-
associated mortality. Despite its significance, the mechanisms governing metastasis are not …
associated mortality. Despite its significance, the mechanisms governing metastasis are not …
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genoty** and longitudinal disease monitoring. However, owing to past emphasis on …
genoty** and longitudinal disease monitoring. However, owing to past emphasis on …
Biologically informed deep neural network for prostate cancer discovery
The determination of molecular features that mediate clinically aggressive phenotypes in
prostate cancer remains a major biological and clinical challenge,. Recent advances in …
prostate cancer remains a major biological and clinical challenge,. Recent advances in …
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase …
Background Metastatic castration-resistant prostate cancer is enriched in DNA damage
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
Genomic correlates of clinical outcome in advanced prostate cancer
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …
through several comprehensive profiling efforts, but little is known about the impact of this …